Cargando…

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib

In this article, we report the design, synthesis, photodynamic properties, and in vitro evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor Talazoparib. In order to yield a photoactivatable, inactive prodrug, photoactivatable protecting groups (PPGs) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiaguo, Xiao, Dian, Liu, Lianqi, Xie, Fei, Li, Wei, Sun, Wei, Yang, Xiaohong, Zhou, Xinbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024556/ https://www.ncbi.nlm.nih.gov/pubmed/31963730 http://dx.doi.org/10.3390/molecules25020407

Ejemplares similares

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors
por: Pinchuk, Boris, et al.
Publicado: (2016)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs
por: Shi, Huayun, et al.
Publicado: (2018)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
por: Lesueur, Paul, et al.
Publicado: (2018)

Facile synthesis of photoactivatable adenosine analogs
por: White, Dawanna S., et al.
Publicado: (2022)

Synthesis and In Vitro Studies of Photoactivatable Semisquaraine-type Pt(II) Complexes
por: Morales, Kevin, et al.
Publicado: (2022)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Facile and General Synthesis of Photoactivatable Xanthene Dyes**
por: Wysocki, Laura M, et al.
Publicado: (2011)

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
por: Attwa, Mohamed W, et al.
Publicado: (2020)

Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates
por: Liu, Lianqi, et al.
Publicado: (2021)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
por: Kohl, Vanessa, et al.
Publicado: (2019)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
por: Zhang, Di, et al.
Publicado: (2019)

Design, Synthesis, and Renal Targeting of Methylprednisolone-Lysozyme
por: Pan, Xingquan, et al.
Publicado: (2020)

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
por: Yu, Jiang, et al.
Publicado: (2022)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
por: Wang, Yanming, et al.
Publicado: (2020)

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
por: Rodon Ahnert, J., et al.
Publicado: (2023)

Design, Synthesis and Biological Evaluation of Brain-Targeted Thiamine Disulfide Prodrugs of Ampakine Compound LCX001
por: Xiao, Dian, et al.
Publicado: (2016)

Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis
por: Earley, Daniel F., et al.
Publicado: (2022)

ESIPT-Based Photoactivatable Fluorescent Probe for Ratiometric Spatiotemporal Bioimaging
por: Zhou, Xiaohong, et al.
Publicado: (2016)

Photoactivatable drugs for nicotinic optopharmacology
por: Banala, Sambashiva, et al.
Publicado: (2018)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA
por: Hirota, Kouji, et al.
Publicado: (2022)

Design, Synthesis, and In Vitro Kinetics Study of Atenolol Prodrugs for the Use in Aqueous Formulations
por: Karaman, Rafik, et al.
Publicado: (2014)

Synthesis and properties of lysosome-specific photoactivatable probes for live-cell imaging
por: Tran, Mai N., et al.
Publicado: (2015)

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate
por: Xiao, Dian, et al.
Publicado: (2021)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_04e2b6n8sds4qh6m0c499564ng